Clinical Trial Update: DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating DZD9008 in combination with Bevacizumab for locally advanced or metastatic non-small cell lung cancer with EGFR mutation, currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• DZD9008

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING